Established in April 2021, Chengdian Biotech is a biotechnology company composed of well-known immunologists and scientists with senior pharmaceutical industry experience. It focuses on unmet clinical needs in tumors and autoimmune diseases and develops a new generation of tumor immunotherapy. With 30 years of accumulation in the field of tumor immunotherapy, the founder, Professor Wang Shengdian, pioneered a treatment strategy to target cytokines to anti-tumor killer T cells. Through the technology platforms ImmuneX and FusionX with independent intellectual property rights, he successfully developed a series of antibody-cytokine fusion proteins.